newsfilter
← Latest News
Business Wire·

Repare Therapeutics to Regain Global Rights to Camonsertib

Repare will regain control of its potential best-in-class oral small molecule ATR inhibitor Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company,